Strategies for combating antibiotic resistance: seeking new solutions

Authors

DOI:

https://doi.org/10.15587/2519-8025.2025.345246

Keywords:

antimicrobial drugs, antibiotic resistance, «One Health», resistant bacteria, biofilms, adjuvants, CRISPR-Cas system

Abstract

The aim: study of innovative world strategies of fight with antibiotic resistance.

Materials and methods. The study was conducted by analyzing available scientific literature, open sources in the databases Google Scholar, PubMed, Clarivate, Web of Science, Scopus, etc., as well as the results of our own research.

The results. The Global Action Plan on Antimicrobial Resistance, developed by WHO, was approved in 2015, and in 2023, it was found that 134 out of 194 countries, including Ukraine, which is 69% of the world's countries, had officially adopted national action plans. However, today there are difficulties in effective communication between all countries and the full implementation of the Global Plan, national action plans due to the fact that developing countries have limited resources for the necessary measures. Antibiotic-resistant bacteria and antibiotic resistance genes are extremely dangerous for human health, which can be compared to a time bomb. Therefore, the fight against antimicrobial resistance requires the consolidation of the work of various industries and should be based on the following areas: the development of partnership programs to optimize the use of antibiotics; the introduction of effective intelligent control and prevention systems; financing programs for the development of new antimicrobial drugs and alternative treatment methods; increased control and intensification of monitoring of the development and spread of resistant microorganisms.

Conclusions. The main reservoirs of antibiotic-resistant bacteria and resistance genes are livestock farms, hospitals, sewage treatment plants and agricultural lands, so the strategy to combat antibiotic resistance should be based primarily on One Health approaches. The solutions proposed by scientists to combat antimicrobial resistance - new antibiotics; pro-, pre-, symbiotic drugs; enzymes for the destruction of biofilms, adhesion inhibitors and associated therapy with adjuvants or phages - have a positive effect, but currently still require regulatory intervention for large-scale use. Effective control of antimicrobial resistance requires investment, training of specialists, raising public awareness, comprehensive policies and regulatory systems that ensure a balance between public health protection and the appropriate use of antibiotics

Author Biographies

Yevheniia Vashchyk, National Scientific Center «Institute of Experimental and Clinical Veterinary Medicine»

Doctor of Veterinary Sciences, Аssociate Professor, Head of Laboratory

Virology Laboratory

Olesya Tsimerman, State Biotechnological University

PhD, Аssociate Professor, Dean

Faculty of Veterinary Medicine

Olena Ladohubets, State Biotechnological University

PhD, Associate Professor

Department of Pharmacology and Parasitology

Kateryna Duchenko, State Biotechnological University

PhD, Associate Professor

Department of Pharmacology and Parasitology

Andriy Zakhariev, State Biotechnological University

PhD, Associate Professor

Department of Normal and Pathological Morphology

Olga Shapovalova, National University of Pharmacy

PhD, Associate Professor, Senior Researcher

Department of Microbiology, Virology and Immunology

References

  1. Wall, S. (2019). Prevention of antibiotic resistance – an epidemiological scoping review to identify research categories and knowledge gaps. Global Health Action, 12 (1). https://doi.org/10.1080/16549716.2020.1756191
  2. Smith, R. A., M’ikanatha, N. M., Read, A. F. (2014). Antibiotic Resistance: A Primer and Call to Action. Health Communication, 30 (3), 309–314. https://doi.org/10.1080/10410236.2014.943634
  3. Bunduki, G. K., Masoamphambe, E., Fox, T., Musaya, J., Musicha, P., Feasey, N. (2024). Prevalence, risk factors, and antimicrobial resistance of endemic healthcare-associated infections in Africa: a systematic review and meta-analysis. BMC Infectious Diseases, 24 (1). https://doi.org/10.1186/s12879-024-09038-0
  4. Gulumbe, B. H., Sahal, M. R., Abdulrahim, A., Faggo, A. A., Yusuf, Z. M., Sambo, K. H. et al. (2023). Antibiotic resistance and the COVID‐19 pandemic: A dual crisis with complex challenges in LMICs. Health Science Reports, 6 (9). https://doi.org/10.1002/hsr2.1566
  5. Ardakani, Z., Aragrande, M., Canali, M. (2024). Global antimicrobial use in livestock farming: an estimate for cattle, chickens, and pigs. Animal, 18 (2), 101060. https://doi.org/10.1016/j.animal.2023.101060
  6. de Lagarde, M., Fairbrother, J. M., Archambault, M., Dufour, S., Francoz, D., Massé, J. et al. (2022). Impact of a Regulation Restricting Critical Antimicrobial Usage on Prevalence of Antimicrobial Resistance in Escherichia coli Isolates From Fecal and Manure Pit Samples on Dairy Farms in Québec, Canada. Frontiers in Veterinary Science, 9. https://doi.org/10.3389/fvets.2022.838498
  7. Bassetti, M., Poulakou, G., Ruppe, E., Bouza, E., Van Hal, S. J., Brink, A. (2017). Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Medicine, 43 (10), 1464–1475. https://doi.org/10.1007/s00134-017-4878-x
  8. Karnwal, A., Jassim, A. Y., Mohammed, A. A., Al-Tawaha, A. R. M. S., Selvaraj, M., Malik, T. (2025). Addressing the global challenge of bacterial drug resistance: insights, strategies, and future directions. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1517772
  9. O’Leary, E. N., Neuhauser, M. M., McLees, A., Paek, M., Tappe, J., Srinivasan, A. (2024). An Update From the National Healthcare Safety Network on Hospital Antibiotic Stewardship Programs in the United States, 2014–2021. Open Forum Infectious Diseases, 11 (2). https://doi.org/10.1093/ofid/ofad684
  10. Liu, L., Li, J., Xin, Y., Huang, X., Liu, C. (2021). Evaluation of wetland substrates for veterinary antibiotics pollution control in lab-scale systems. Environmental Pollution, 269, 116152. https://doi.org/10.1016/j.envpol.2020.116152
  11. Villarreal, C. L., Price, M. A., Moreno, A. N., Zenteno, A., Saenz, C., Toppo, A. et al. (2023). Regulatory challenges in conducting human subjects research in emergency settings: the National Trauma Research Action Plan (NTRAP) scoping review. Trauma Surgery & Acute Care Open, 8 (1), e001044. https://doi.org/10.1136/tsaco-2022-001044
  12. Antimicrobial consumption and resistance in bacteria from humans and food-producing animals: Fourth joint inter-agency report on integrated analysis of antimicrobial agent consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA JIACRA IV – 2019–2021 (2024). EFSA journal. European Food Safety Authority, 22 (2), e8589. https://doi.org/10.2903/j.efsa.2024.8589
  13. Willemsen, A., Reid, S., Assefa, Y. (2022). A review of national action plans on antimicrobial resistance: strengths and weaknesses. Antimicrobial Resistance & Infection Control, 11 (1). https://doi.org/10.1186/s13756-022-01130-x
  14. Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., Dias da Silva, D. (2024). An Overview of the Recent Advances in Antimicrobial Resistance. Microorganisms, 12 (9), 1920. https://doi.org/10.3390/microorganisms12091920
  15. Magiorakos, A. P., Burns, K., Rodríguez Baño, J., Borg, M., Daikos, G., Dumpis, U. et al. (2017). Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrobial Resistance & Infection Control, 6 (1). https://doi.org/10.1186/s13756-017-0259-z
  16. Pitout, J. D. D. (2019). Transmission Surveillance for Antimicrobial-Resistant Organisms in the Health System. Microbial Transmission, 215–227. https://doi.org/10.1128/9781555819743.ch12
  17. Aarestrup, F. M., Woolhouse, M. E. J. (2020). Using sewage for surveillance of antimicrobial resistance. Science, 367 (6478), 630–632. https://doi.org/10.1126/science.aba3432
  18. Salam, Md. A., Al-Amin, Md. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., Alqumber, M. A. A. (2023). Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare, 11 (13), 1946. https://doi.org/10.3390/healthcare11131946
  19. Robinson, T. P., Bu, D. P., Carrique-Mas, J., Fèvre, E. M., Gilbert, M., Grace, D. et al. (2016). Antibiotic resistance is the quintessential One Health issue. Transactions of The Royal Society of Tropical Medicine and Hygiene, 110 (7), 377–380. https://doi.org/10.1093/trstmh/trw048
  20. Lam, T. J. G. M., Jansen, J., Wessels, R. J. (2017). The RESET Mindset Model applied on decreasing antibiotic usage in dairy cattle in the Netherlands. Irish Veterinary Journal, 70 (1). https://doi.org/10.1186/s13620-017-0085-x
  21. O’Brien, L. M., Walsh, E. J., Massey, R. C., Peacock, S. J., Foster, T. J. (2002). Staphylococcus aureusclumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cellular Microbiology, 4 (11), 759–770. https://doi.org/10.1046/j.1462-5822.2002.00231.x
  22. Von Mentzer, A., Zalem, D., Chrienova, Z., Teneberg, S. (2020). Colonization factor CS30 from enterotoxigenic Escherichia coli binds to sulfatide in human and porcine small intestine. Virulence, 11 (1), 381–390. https://doi.org/10.1080/21505594.2020.1749497
  23. Akhtar, M., Chowdhury, M. I., Bhuiyan, T. R., Kaim, J., Ahmed, T., Rafique, T. A. et al. (2019). Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses. Vaccine, 37 (37), 5645–5656. https://doi.org/10.1016/j.vaccine.2018.11.040
  24. Krachler, A. M., Orth, K. (2013). Targeting the bacteria–host interface. Virulence, 4 (4), 284–294. https://doi.org/10.4161/viru.24606
  25. Hachani, A., Wood, T. E., Filloux, A. (2016). Type VI secretion and anti-host effectors. Current Opinion in Microbiology, 29, 81–93. https://doi.org/10.1016/j.mib.2015.11.006
  26. Balta, I., Linton, M., Pinkerton, L., Kelly, C., Ward, P., Stef, L. et al. (2021). The effect of natural antimicrobials on the Campylobacter coli T6SS+/− during in vitro infection assays and on their ability to adhere to chicken skin and carcasses. International Journal of Food Microbiology, 338, 108998. https://doi.org/10.1016/j.ijfoodmicro.2020.108998
  27. Gill, E. E., Franco, O. L., Hancock, Robert. E. W. (2014). Antibiotic Adjuvants: Diverse Strategies for Controlling Drug‐Resistant Pathogens. Chemical Biology & Drug Design, 85 (1), 56–78. https://doi.org/10.1111/cbdd.12478
  28. Filby, B. W., Weldrick, P. J., Paunov, V. N. (2022). Overcoming Beta-Lactamase-Based Antimicrobial Resistance by Nanocarrier-Loaded Clavulanic Acid and Antibiotic Cotreatments. ACS Applied Bio Materials, 5 (8), 3826–3840. https://doi.org/10.1021/acsabm.2c00369
  29. Anusha, M., Tejaswini, V., Udhaya Kumar, S., Prashantha, C. N., Vasudevan, K., George Priya Doss, C. (2023). Gene network interaction analysis to elucidate the antimicrobial resistance mechanisms in the Clostridium difficile. Microbial Pathogenesis, 178, 106083. https://doi.org/10.1016/j.micpath.2023.106083
  30. Bhavnani, S. M., Krause, K. M., Ambrose, P. G. (2020). A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development. Open Forum Infectious Diseases, 7 (7). https://doi.org/10.1093/ofid/ofaa083
  31. Fotina, T. I., Vashchyk, Ye. V., Fotina, H. A. (2017). Antimicrobial properties of the preparation «Sarofloks» towards pathogens of birds bacterial infections. Veterynarna medytsyna, 103, 227–230.
  32. Al-Madboly, L. A., Aboulmagd, A., El-Salam, M. A., Kushkevych, I., El-Morsi, R. M. (2024). Microbial enzymes as powerful natural anti-biofilm candidates. Microbial Cell Factories, 23 (1). https://doi.org/10.1186/s12934-024-02610-y
  33. Wu, Y., Battalapalli, D., Hakeem, M. J., Selamneni, V., Zhang, P., Draz, M. S., Ruan, Z. (2021). Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. Journal of Nanobiotechnology, 19 (1). https://doi.org/10.1186/s12951-021-01132-8
  34. Nagy, E., Nagy, G., Power, C. A., Badarau, A., Szijártó, V.; Lim, T. (Eds.) (2017). Anti-bacterial Monoclonal Antibodies. Recombinant Antibodies for Infectious Diseases. Cham: Springer, 119–153. https://doi.org/10.1007/978-3-319-72077-7_7
  35. Saeed, U., Insaf, R. A., Piracha, Z. Z., Tariq, M. N., Sohail, A., Abbasi, U. A. et al. (2023). Crisis averted: a world united against the menace of multiple drug-resistant superbugs -pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1270018
Strategies for combating antibiotic resistance: seeking new solutions

Downloads

Published

2025-09-30

How to Cite

Vashchyk, Y., Tsimerman, O., Ladohubets, O., Duchenko, K., Zakhariev, A., & Shapovalova, O. (2025). Strategies for combating antibiotic resistance: seeking new solutions. ScienceRise: Biological Science, (3 (44), 32–39. https://doi.org/10.15587/2519-8025.2025.345246

Issue

No. 3 (44) (2025)

Section

Veterinary research

License

Copyright (c) 2025 Yevheniia Vashchyk, Olesya Tsimerman, Olena Ladohubets, Kateryna Duchenko, Andriy Zakhariev, Olga Shapovalova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.